Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibetan irritable bowel syndrome gut microbiota study with trimebutine and probiotic treatment
ChiCTR1900025125Phase 4Recruiting
- Sponsor
- Hospital of Chengdu Office of the People's Government of Tibet Autonomous Region
- Start
- Jul 2019
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of trimebutine, bacillus licheniformis and bacillus subtilis in irritable bowel syndrome (IBS) (2 arms), sponsored by Hospital of Chengdu Office of the People's Government of Tibet Autonomous Region. Primary endpoint: Stool flora. Started Jul 2019; status: recruiting.
02
Drugs
trimebutinebacillus licheniformisbacillus subtilis
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on ChiCTR1900025125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025125.